Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 50/100

Failure Rate

7.7%

7 terminated/withdrawn out of 91 trials

Success Rate

76.7%

-9.8% vs industry average

Late-Stage Pipeline

21%

19 trials in Phase 3/4

Results Transparency

13%

3 of 23 completed trials have results

Key Signals

12 recruiting3 with results

Enrollment Performance

Analytics

Phase 2

53(63.1%)

Phase 3

17(20.2%)

Phase 1

6(7.1%)

N/A

6(7.1%)

Phase 4

2(2.4%)

84Total

Phase 2(53)

Phase 3(17)

Phase 1(6)

N/A(6)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (91)

Showing 20 of 91 trials

NCT06892054Phase 1Recruiting

Sotorasib Combined With First-line Chemotherapy for Advanced Pancreatic Adenocarcinoma

Role: collaborator

NCT05528952Phase 2Recruiting

Evaluation of the Interest to Combine a CD4 Th1-inducer Cancer Vaccine Derived From Telomerase and Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma

Role: collaborator

NCT02959879Phase 2Completed

Neo-adjuvant FOLF(IRIN)OX for Resectable Pancreatic Adenocarcinoma

Role: collaborator

NCT06253611Phase 2Recruiting

First-line EXL01 With Nivolumab and FOLFOX for PD-L1 CPS ≥5 Metastatic Gastric Cancer

Role: lead

NCT04166604Phase 2Active Not Recruiting

LONsurf and G-CSF Use: Being On A Right Dose-intensity to Optimize Treatment Efficacy

Role: lead

NCT00665392Phase 2Completed

Cetuximab and Combination Chemotherapy in Patients With Stage III-IV Resectable Oropharynx Cancer

Role: lead

NCT03806309Phase 2Active Not Recruiting

OSE2101+FOLFIRI, or FOLFIRI Maintenance After FOLFIRINOX-based Induction Therapy in Advanced or Metastatic PDAC

Role: lead

NCT04348045Phase 2Active Not Recruiting

Maintenance With Olaparib or Selumetinib + Durvaluma for m-PDAC Guided by BRCAness and KRAS Status.

Role: lead

NCT03350126Phase 2Active Not Recruiting

iRECIST Evaluation's Relevance for DCR in MMR/MSI Metastatic Colorectal Cancer Patients on Nivolumab and Ipilimumab

Role: lead

NCT05787197Recruiting

ctDNA in CRC Patients Undergoing Curative-intent Surgery for Liver Metastases

Role: lead

NCT03704480Phase 2Active Not Recruiting

Durvalumab + Tremelimumab ± Paclitaxel in Advanced BTC After Platinum Chemotherapy.

Role: lead

NCT04268121Phase 2Recruiting

Efficacy of Neoadjuvant Chemotherapy in Terms of DFS in Patients With Localized Digestive Neuroendocrine Carcinomas

Role: lead

NCT05850130Not ApplicableRecruiting

Acupuncture for Oxaliplatin-induced Peripheral Neuropathy in Gastro-intestinal Cancer Patients

Role: lead

NCT04935853Recruiting

Prognostic and Predictive Markers of Response to Treatment in Patients With Bile Duct Cancer: ACABi PRONOBIL Study

Role: lead

NCT03828227Phase 3Active Not Recruiting

QoL in mCRC Elderly Patients Receiving First-line Therapy Based on Simplified Geriatric Parameters.

Role: lead

NCT06275737Not ApplicableRecruiting

POP-UP: a Single-arm, Two-cohort Study: Trimodal Prehab for Upper GI and Pancreatic Cancer

Role: lead

NCT07071844Phase 2Not Yet Recruiting

BETWEEN: Biweekly Bevacizumab + Trifluridine/Tipiracil to Reduce Grade 3-4 Neutropenia in mCRC Patients

Role: lead

NCT04906954Not ApplicableWithdrawn

Combined Neuromuscular Electrical Stimulation and Nutritional Support for Advanced Gastrointestinal Cancer Patients.

Role: lead

NCT05310643Phase 2Recruiting

Nivolumab and Ipilimumab in Anti-PD1-Resistant dMMR/MSI mCRC

Role: lead

NCT07028424Phase 2Not Yet Recruiting

PANORAMIX : Optimizing 1st-line NALIRIFOX and Exploring Microbiota's Role in 2nd Line Pancreatic Cancer Treatment

Role: lead